Superluminal Medicines closed an oversubscribed $60 million Series B to advance its obesity program into a first clinical study. The company is building next-generation small-molecule GPCR-targeted therapies aimed at endocrine and cardiometabolic indications, using AI and structural biology to pursue challenging GPCR targets. The financing underscores continued investor appetite for therapeutic areas tied to cardiometabolic disease, particularly where platform differentiation is tied to target selection and drug discovery speed. Superluminal’s Series B is positioned to translate its preclinical efforts into early human testing. For the sector, the round signals that obesity remains a capital-attracting category, with developers competing on mechanism novelty and ability to move into clinic quickly.